Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

NCT01622868
Breast cancer type: HER2+
Recruitment status: Recruiting
Phase 2
Interventions: Other: Laboratory Biomarker Analysis|Drug: Lapatinib Ditosylate|Radiation: Stereotactic Radiosurgery|Radiation: Whole-Brain Radiotherapy
Drug category:

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of metastases: Brain
Additional Notes:
Exclusions: Leptomeningeal disease
https://ClinicalTrials.gov/show/NCT01622868

Comments are closed.

Up ↑